# US 2025/0082774 A1 · Peptide linkers comprising two or more payloads

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082774 A1
- Document ID: US20250082774A1
- Status: Published application
- Kind: A1
- Application number: 18/803,344
- Filed: 2024-08-13
- Published: 2025-03-13
- Earliest claimed: 2022-02-22
- Assignees: Araris Biotech AG
- Applicants: Araris Biotech AG
- Inventors: Romain BERTRAND; Isabella ATTINGER-TOLLER; Rachael FAY; Dragan GRABULOVSKI; Philipp SPYCHER
- Web page: https://patentgrep.com/patent/US20250082774A1

## CPC

- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/32: against translation products of oncogenes
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a peptide linker comprising (a) an amino acid residue comprising a primary amine; and (b) two or more payloads; wherein each of the two or more payloads can be independently attached to: (i) an N-terminal end of the peptide linker, (ii) a C-terminal end of the peptide linker, or (iii) a side chain of an amino acid residue comprised in the peptide linker. Further, the present invention relates to antibody-payload conjugates comprising the peptide linker of the invention, methods for generating said antibody-payload conjugates and uses thereof.

## Claims

### Claim 1

A peptide linker comprising
a) an amino acid residue comprising a primary amine; and
b) two or more payloads;
wherein each of the two or more payloads can be independently attached to:
i) an N-terminal end of the peptide linker,
ii) a C-terminal end of the peptide linker, or
iii) a side chain of an amino acid residue comprised in the peptide linker.

### Claim 2 (depends on 1)

The peptide linker according to claim 1, wherein the primary amine comprised in the amino acid residue is
a) a primary amine in a side chain of a lysine, a lysine derivative or a lysine mimetic; or
b) a primary amine comprised in an N-terminal amino acid residue having the structure NH2—(Y)—COOH.

### Claim 3 (depends on 2)

The peptide linker according to claim 2, wherein Y is (R2C)n and wherein n is an integer ranging from 1 to 20, from 1 to 15, from 1 to 10.

### Claim 4 (depends on 3)

The peptide linker according to claim 3, wherein at least one R moiety of each —(R2C)— monomer is hydrogen or wherein both R moieties of each —(R2C)— monomer are hydrogen.

### Claim 5 (depends on 1)

The peptide linker according to claim 1, wherein the linker comprises not more than 25 amino acid residues.

### Claim 6 (depends on 1)

The peptide linker according to claim 1, wherein the linker comprises at least one arginine and/or histidine residue.

### Claim 7 (depends on 1)

The peptide linker according to claim 1, wherein the linker comprises the sequence motif RK.

### Claim 8 (depends on 1)

The peptide linker according to claim 1, wherein the linker comprises any one of the amino acid sequences set forth in SEQ ID NO:1-29 or 82-93.

### Claim 9 (depends on 1)

The peptide linker according to claim 1, wherein the linker comprises between 2 and 4 payloads.

### Claim 10 (depends on 1)

The peptide linker according to claim 1, wherein the linker consists of or comprises the following structure (in N->C direction):
[payload1]-[(Aa)m-(Lys)-(Aa)n-(Arg/His)-(Aa)o]-[payload2]; wherein
[payload 1] and [payload 2] are payloads,
(Aa) may be any amino acid residue;
m, n and o may be integers ranging from 0 to 10;
(Arg) may be an arginine residue, an arginine mimetic or an arginine derivative;
(His) may be a histidine residue, a histidine mimetic or a histidine derivative
(Lys) is a lysine residue, a lysine mimetic or a lysine derivative,
wherein [payload 1] is directly or indirectly attached to an N-terminal end of an (Aa) or (Lys) residue, and
wherein [payload 2] is directly or indirectly attached to a C-terminal end of an (Aa) or (Arg/His) residue.

### Claim at position 11

11-19. (canceled)

### Claim 20 (depends on 1)

The peptide linker according claim 1, wherein at least one payload is attached to a side chain of an amino acid residue comprised in the peptide linker.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The peptide linker according to claim 1, wherein the peptide linker comprises two peptide moieties, and wherein the two peptide moieties are connected via their N-terminal amino acid residues with a dicarboxylic acid linker, or an activated version thereof.

### Claim 23 (depends on 22)

The peptide linker according to claim 22, wherein the linker comprises the structure:
[payload1]-[peptide1]-[dicarboxylic acid]-[peptide2]-[payload2]; wherein
[payload 1] and [payload 2] are payloads,
[peptide 1] is a first peptide moiety,
[peptide 2] is a second peptide moiety, and
[dicarboxylic acid] is a dicarboxylic acid;
wherein at least one of [peptide 1] and/or [peptide 2] comprises a free amine,
wherein the N-terminal end of [peptide 1] and the N-terminal end of [peptide 2] are connected via the dicarboxylic acid,
wherein [payload 1] is attached to the C-terminal end of [peptide 1], and
wherein [payload 2] is attached to the C-terminal end of [peptide 2] linker.

### Claim at position 16

24-28. (canceled)

### Claim 29

An antibody-payload conjugate comprising an antibody conjugated to a peptide linker comprising
a) an amino acid residue comprising a primary amine; and
b) two or more payloads;
wherein each of the two or more payloads can be independently attached to:
i) an N-terminal end of the peptide linker,
ii) a C-terminal end of the peptide linker, or
iii) a side chain of an amino acid residue comprised in the peptide linker.

### Claim 30 (depends on 29)

The antibody-payload conjugate according to claim 29, wherein the peptide linker is conjugated to the antibody via an isopeptide bond formed between a γ-carboxamide group of a glutamine residue comprised in the antibody and the primary amine comprised in an amino acid residue of the peptide linker.

### Claim 31

(canceled)

### Claim 32 (depends on 29)

The antibody-payload conjugate according to claim 29, wherein the peptide linker is conjugated to a glutamine residue comprised in an Fc domain of the antibody.

### Claim 33 (depends on 32)

The antibody-payload conjugate according to claim 32, wherein the glutamine residue to which the peptide linker is conjugated is glutamine residue Q295 (EU numbering) of the CH2 domain of an IgG antibody.

### Claim 34

(canceled)

### Claim 35 (depends on 32)

The antibody-payload conjugate according to claim 32, wherein the glutamine residue to which the peptide linker is conjugated is glutamine residue N297Q (EU numbering) of the CH2 domain of an aglycosylated IgG antibody.

### Claim at position 24

36-37. (canceled)

### Claim 38 (depends on 29)

The antibody-payload conjugate according to claim 29, wherein the antibody is a glycosylated IgG antibody.

### Claim 39 (depends on 38)

The antibody-payload conjugate according to claim 38, wherein the IgG antibody is glycosylated at residue N297 (EU numbering) of the CH2 domain.

### Claim at position 27

40-42. (canceled)

### Claim 43

A method for the preparation of an antibody-payload conjugate comprising a step of conjugating a peptide linker to an antibody, wherein the peptide linker comprises
a) an amino acid residue comprising a primary amine; and
b) two or more payloads;
wherein each of the two or more payloads can be independently attached to:
i) an N-terminal end of the peptide linker,
ii) a C-terminal end of the peptide linker, or
iii) a side chain of an amino acid residue comprised in the peptide linker.

### Claim 44

A method for the conjugation of a peptide linker comprising two or more payloads to an antibody using a transglutaminase (TG), the method comprising a) mixing the antibody, the peptide linker and the TG within a fluid, thereby conjugating the linker-payload to the antibody in one step under the catalyzing effect of the TG, and b) extracting the conjugate obtained in step a) from the fluid.

### Claim at position 30

45-69. (canceled)

### Claim 70 (depends on 29)

A pharmaceutical composition comprising the antibody-payload conjugate according to claim 29 and at least one pharmaceutically acceptable ingredient.

### Claim at position 32

-81. (canceled)

### Claim 82

A method of treating or preventing a neoplastic disease, said method comprising administering to a patient in need thereof an antibody-payload conjugate comprising an antibody conjugated to a peptide linker comprising
a) an amino acid residue comprising a primary amine; and
b) two or more payloads;
wherein each of the two or more payloads can be independently attached to:
i) an N-terminal end of the peptide linker,
ii) a C-terminal end of the peptide linker, or
iii) a side chain of an amino acid residue comprised in the peptide linker.
